Reducing short-acting beta-agonist overprescribing in asthma
نویسندگان
چکیده
منابع مشابه
Prescription of oral short-acting beta 2-agonist for asthma in non-resource poor settings: A national study in Malaysia
OBJECTIVE Use of oral short-acting beta 2-agonist (SABA) persists in non-resource poor countries despite concerns for its lower efficacy and safety. Utilisation and reasons for such use is needed to support the effort to discourage the use of oral SABA in asthma. This study examined the frequency of oral short-acting Beta 2-agonist (SABA) usage in the management of asthma in primary care and de...
متن کاملSafety of Long - Acting Beta - Agonists in Asthma ASTHMA THERAPY
THE EUROPEAN JOURNAL OF RESPIRATORY MEDICINE VOL I ISSUE I Although there was no attempt to determine degree of adherence with ICS at randomisation or persistence in their use during the course of the study, no significant differences were seen for primary events and asthma-related events, including deaths in the total population of patients receiving ICS at baseline. However, in the total popu...
متن کاملOveruse of short-acting beta-agonist bronchodilators in COPD during periods of clinical stability.
BACKGROUND Overuse of short-acting beta-agonists (SABA) is described in asthma, but little is known about overuse of SABA in chronic obstructive pulmonary disease (COPD). METHODS Prospective 3-month cohort study of patients with moderate-to-severe COPD who were provided a portable electronic inhaler sensor to monitor daily SABA use. Subjects wore a pedometer for 3 seven-day periods and were a...
متن کاملSafety of long-acting beta agonists in adults with asthma.
Practice Pointers Asthma affects 8.2% of the U.S. population, and disproportionately affects those who are poor and black. Despite effective therapies, 3,404 U.S. deaths were attributed to asthma in 2010.1 Two types of inhaled pharmacologic agents are used for asthma control: inhaled corticosteroids and LABAs. Concerns about the safety of LABAs have risen with reports of increased hospital admi...
متن کاملSafety of Long-Acting Beta-Agonists in Children with Asthma.
n engl j med 375;9 nejm.org September 1, 2016 889 globulin mucin 3 (TIM-3) or other checkpoints,4 and recently identified mechanisms of primary resistance to PD-1–PD-L1 blockade, which include transcriptional signatures in the tumor microenvironment (innate anti–PD-1 resistance signature, or IPRES5) and the presence of somatic differences in tumor cells (constitutive activation of β-catenin6 or...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of General Practice
سال: 2022
ISSN: ['0960-1643', '1478-5242']
DOI: https://doi.org/10.3399/bjgp22x720485